Clinical trial

Low Dose Atropine For Symptomatic Vitreous Floaters

Name

1362664

Description

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

Trial arms

Trial start

2024-01-01

Estimated PCD

2024-06-01

Trial end

2024-06-01

Status

Not yet recruiting

Phase

Early phase I

Treatment

0.01% atropine ophthalmic drop

0.01% atropine ophthalmic drop will be applied daily to the affected eye

Arms:

Atropine 0.01%

Size

200

Primary endpoint

Symptom improvement assessed by questionnaire

Up to 2 months

Eligibility criteria

Inclusion Criteria: * Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants. Exclusion Criteria: * Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 200, 'type': 'ESTIMATED'}}

Updated at

2023-12-18

1 organization

1 product

1 indication

Organization

Jeanette Du

Product

Atropine Ophthalmic

Indication

vitreous floaters